Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Sutro Biopharma, Inc. (STRO) had Consolidated Net Income/Loss of $-46.76M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$11.65M |
|
$-46.76M |
|
-- |
|
$11.65M |
|
$49.70M |
|
$-38.05M |
|
$-8.79M |
|
$-46.84M |
|
$-46.84M |
|
$-46.76M |
|
$-46.76M |
|
|
Consolidated Net Income/Loss |
$-46.76M |
$-46.76M |
|
$-38.05M |
|
$-36.96M |
|
8.50M |
|
8.50M |
|
$-5.29 |
|
$-5.29 |
|
| Balance Sheet Financials | |
$150.93M |
|
$10.65M |
|
$22.90M |
|
$173.83M |
|
$75.13M |
|
-- |
|
$231.15M |
|
$306.28M |
|
$-132.45M |
|
$-132.45M |
|
$-132.45M |
|
8.58M |
|
| Cash Flow Statement Financials | |
$-177.23M |
|
$45.01M |
|
$0.04M |
|
$191.16M |
|
$58.99M |
|
$-132.17M |
|
$14.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-326.69% |
|
-326.69% |
|
-- |
|
-402.14% |
|
-401.49% |
|
$-178.93M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
2.93 |
|
30.73 |
|
35.30% |
|
35.30% |
|
-26.90% |
|
35.30% |
|
$-15.43 |
|
$-21.06 |
|
$-20.86 |
|